[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Tennessee\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":496},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,49,77,111,139,174,209,234,262,289,314,336,359,388,412,433,453,475],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100645249","influence-of-a-parent-mediated-mhealth-motor-skill-intervention-on-preschool-childrens-motor-skills-and-cognitive-function-100645249",false,"NCT07680075","Influence of a Parent-mediated mHealth Motor Skill Intervention on Preschool Children's Motor Skills and Cognitive Function","COSMIC","Inclusion Criteria:\n\n* Children will be included if they are 3-5 years of age at the time of enrollment and their accompanying parents (Age 18 or above).\n\nExclusion Criteria:\n\n* Child exclusion criteria: Physical or cognitive disability that parent feels will preclude participation in activity breaks or assessments (physical activity or gross motor skill activities).\n\nParent exclusion criteria: No parental access to a smartphone, tablet or computer; physical limitation that impairs modeling of activities; parent cannot read and understand English.",true,"ALL","3 Years","5 Years",{"count":21,"type":22},35,"ESTIMATED","INTERVENTIONAL",[25],"NA","The proposed study uses a mHealth application \"app\" to help parents teach their preschool-age child motor skill (FMS) activities in the home environment. This app guides families to participate in 10-min activity breaks, 7 days\u002Fweek for 12 weeks and the app includes weekly instructional lessons, peer modeling videos, behavioral scaffolding, and structured activities. This study builds on prior work by assessing whether improvements in FMS generalize to cognitive domains, including executive function skills such as working memory, attention, and inhibitory control. By examining both motor and cognitive outcomes, the project will provide essential evidence on whether enhanced FMS uniquely contributes to cognitive development. Based on findings from the proposed study, there may be a need to develop additional modules that address diverse needs of children or that contribute to broader, multifaceted improvement in both motor competence and cognitive function. Findings will inform the potential of technology-based motor skill interventions to support broader aspects of child development in diverse populations, guiding future practice and policy in education, health, and early intervention.",[28,29,30],"Executive Function","Motor Skills","Healthy",[32,33,34,35,36],"mHealth","preschool","motor skill","executive function","parent-mediated","NOT_YET_RECRUITING","2026-06-25",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":22},"2026-06-30",{"date":45,"type":22},"2027-06-30",{"name":47,"class":48},"University of Tennessee","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100642608","phase-2-cbd-knee-osteoarthritis-study-100642608","NCT07638189","CBD Knee Osteoarthritis Study","Pilot Study Using Topical Cannabidiol (CBD) to Manage Osteoarthritic Knee Pain","Inclusion Criteria:\n\n1. Knee OA (grade 2-3 as measured by the Kellgren-Lawrence Classification)\n2. OA knee pain on the Visual Analog Pain Scale \\> 4 in either knee\n3. Receiving treatment at one of the eight Campbell Clinic Orthopaedics locations\n\nExclusion Criteria:\n\n1. Other forms of arthritis such as psoriatic arthritis or rheumatoid arthritis due to different sources of inflammation in these conditions\n2. Allergies to CBD or Castor Oil\n3. Current opioid use\n4. BMI of over 40\n5. Those who cannot walk without an assistance device (e.g., walker)\n6. Those who are currently on knee injections (i.e. cortisol or hyaluronic acid gel) for knee pain\n7. Patients scheduled for a knee replacement in the next 3-6 months\n8. Active cannabis or CBD use\n9. Alcohol consumption \\> 21 alcoholic drinks each week\n10. Active pregnancy, nursing, or actively planning a pregnancy\n11. Active chronic liver or renal disease\n12. Active depression\u002Fsuicidality\n13. Medications that interact with CBD in the liver that cannot be discontinued 14. Discretion of the Multiple Principal Investigators for concerns regarding noncompliance with the study intervention.","21 Years",{"count":58,"type":22},30,[60],"PHASE2","Osteoarthritis of the knee is a common cause of pain in the US. The currently available medicines for knee osteoarthritis sometimes are not effective at relieving the pain or have unacceptable side effects. Thus, alternate pain relieving treatments are needed.\n\nCBD, an active chemical from the hemp derived cannabis sativa plant, has received a lot of attention for its potential pain relieving properties, but there has been limited research to find out if topically applied CBD can decrease pain from knee osteoarthritis. CBD lacks the psychoactive effects seen with marijuana use, because it does not contain THC which is responsible for those effects in marijuana. It is legal to use CBD in the State of Tennessee (site of study).\n\nThe CBD Knee Study is sponsored by the University of Tennessee Health Science Center and is a collaborative effort between doctors at UT and Campbell Clinic. In the CBD Knee Study, the investigators are examining whether topically applied CBD dissolved in Castor Oil will relieve knee pain in persons with knee osteoarthritis.\n\nPersons who take part in the study would need to come for study visits, fill out questionnaires about their health and knee pain, and would be asked to use the topical study oil on their knees. Taking part in the CBD Knee Study is voluntary.",[63],"Osteoarthitis",[65,66,67],"Randomized Clinical Trial","Cannabidiol (CBD)","Knee Pain","2026-06-04",{"date":70,"type":41},"2026-06-10",{"date":72,"type":22},"2026-07-01",{"date":74,"type":22},"2028-03-30",{"name":47,"class":48},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":76},"100587189","phase-4-comfort-trial-complex-obstetric-management-with-focused-regional-transversus-abdominis-plane-block-100587189","NCT06925152","COMFORT Trial: Complex Obstetric Management With Focused Regional Transversus Abdominis Plane Block","COMFORT","Inclusion criteria:\n\nPatient has a history of a least one of the following:\n\n* Prior exploratory laparotomy\n* History of non-obstetric open intra-abdominal surgery\n* History of three or more prior cesarean deliveries\n* History of intra-abdominal or pelvic adhesive disease\n* History of abdominoplasty\n* History of abdominal re-exploration surgery\n\nExclusion Criteria:\n\n* Received general anesthesia\n* History of less than 3 cesarean deliveries if do not meet other inclusion criteria\n* History of chronic opioid use\n* History of substance abuse (i.e. alcohol, methamphetamine\u002Famphetamine, abuse of prescription opioid medication, or heroin use)\n* History of chronic kidney disease\n* Allergies to bupivacaine or oral analgesics\n* Patient preference\n* Cesarean hysterectomy\n* Administration of ≥4mg morphine to epidural\n* Loss to follow-up","FEMALE","18 Years","50 Years",{"count":88,"type":22},120,[90],"PHASE4","To assess the effect of intraoperative transversus abdominis plane (TAP) blocks on the amount of opioid pain medications expressed as morphine milliequivalents (MME) used postoperatively in patients who have undergone cesarean delivery (CD) in the setting of complex obstetric surgery (COS).",[93,94,95,96],"Complex Obstetric Surgery","Perioperative Pain Management","Cesarean Delivery","Postoperative Pain Control",[98,99,100,101],"Complex obstetric surgery","Perioperative pain management","cesarean delivery","postoperative pain control","RECRUITING","2026-03-08",{"date":105,"type":41},"2026-03-11",{"date":107,"type":41},"2025-07-15",{"date":109,"type":22},"2028-05",{"name":47,"class":48},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":76},"100628729","phase-4-pharmacokinetic-analysis-of-cefiderocol-in-patients-with-acute-burn-injuries-100628729","NCT07465432","Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries","Inclusion Criteria:\n\n* age ≥ 18 and ≤ 80 years old\n* estimated CLCR (eCLCR) ≥ 60 mL\u002Fmin via Cockcroft-Gault equation\n\nExclusion Criteria:\n\n* KDIGO classification ≥ 1 at day of screening\n* known HIV or HBV infection","80 Years",{"count":119,"type":22},12,[90],"Cefiderocol is a powerful, broad spectrum antibiotic approved to treat hospital-acquired or ventilator associated pneumonia and urinary tract infections. Although cefiderocol has labeled dosing recommendations, including augmented renal clearance, patients with burn injury remain an unstudied population at high risk for MDR pathogens. The primary objective of this study is to evaluate the pharmacokinetic principles of cefiderocol in patients after acute burn injury. Findings from this study will determine the dose and interval necessary to maintain therapeutic concentrations of cefiderocol in patients after burn injury for adequate bactericidal activity, prevention of resistance, and treatment outcomes.",[123],"Drug Clearance After Severe Burn Injury",[125,126,127,128,129,130],"burns","cefiderocol","pharmacokinetics","pharmacodynamics","augmented renal clearance","Gram-negative bacterial infections","2026-03-05",{"date":133,"type":41},"2026-03-12",{"date":135,"type":22},"2026-02-16",{"date":137,"type":22},"2027-02-28",{"name":47,"class":48},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},"100544852","pharmacy-led-transitions-of-care-intervention-to-improve-medication-adherence-100544852","NCT06374277","Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence","Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations","MedAAAction","Inclusion Criteria:\n\n* Medicaid or uninsured inpatients\n* 21 years or older\n* ≥2 of the complex chronic conditions during index admission or prescribed\u002Fusing ≥2 chronic medications for these conditions\n* Patients receiving chronic disease medications from the hospital pharmacy.\n* Patients will be eligible if they have multiple complex chronic conditions including diabetes, hypertension, high cholesterol, coronary artery disease, congestive heart failure, chronic lung disease, chronic kidney disease, arrhythmia, stroke, psychiatric disorders including depression and anxiety, or who are prescribed or using anticoagulants.\n\nExclusion Criteria:\n\n* Medicare and Medicaid dual eligible patients.\n* If the primary reason for the index admission is related to cancer, pregnancy, or a surgical procedure for an acute problem\n* If patients have diagnoses of active psychosis, substance abuse, or suicidal ideation during the index admission.\n* If the planned discharge location is not home.\n* If patients are part of an existing pharmacy discharge program.",{"count":148,"type":22},388,[25],"Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians\u002Fhealth coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.",[152,153,154,155,156,157,158,159,160,161,162,163,164],"Diabetes","Hypertension","High Cholesterol\u002FHyperlipidemia","Coronary Artery Disease","Congestive Heart Failure","Chronic Lung Disease","Chronic Kidney Diseases","Arrythmia","Stroke","Depression","Anxiety","Pulmonary Embolism","Heart Attack","2026-01-27",{"date":167,"type":41},"2026-01-29",{"date":169,"type":41},"2024-04-06",{"date":171,"type":22},"2028-01-31",{"name":47,"class":48},2,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":190,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":173},"100610295","access-to-care-pilot-for-ed-presenting-head-and-neck-cancer-patients-enrich-hnc-100610295","NCT07225725","Access to Care Pilot for ED-Presenting Head and Neck Cancer Patients (ENRICH-HNC)","Community Health Support for Emergency Department-Presenting Head and Neck Cancer Patients: A Pilot to Improve Access to Timely Care","ENRICH-HNC","Inclusion Criteria\n\n* Age 18 years or older\n* Presentation to the emergency department (ED) with a new or suspected head and neck cancer (including oral cavity, oropharynx, hypopharynx, larynx, salivary gland, cutaneous, sinonasal, nasopharyngeal, thyroid, or metastatic disease with unknown primary)\n* Residence within the regional catchment area of participating UTHSC-affiliated hospitals (Methodist University Hospital or Regional One Health)\n* Ability to provide informed consent electronically using REDCap eConsent after ED discharge\n* Has a valid telephone number for post-discharge contact\n\nExclusion Criteria\n\n* Prior or ongoing established head and neck oncology care at the time of ED presentation\n* Currently receiving hospice or palliative-only care\n* Incarcerated individuals\n* Inability to complete electronic informed consent (e.g., lack of decisional capacity or inability to complete consent even with staff assistance)\n* Lacks reliable telephone access or is unable to be reached after three documented contact attempts by study staff\n* Non-English or non-Spanish speaking when interpreter services are unavailable\n* Expected survival less than four weeks, as determined by the treating clinical team",{"count":183,"type":22},24,[25],"Patients diagnosed with head and neck cancer (HNC) after presenting to an emergency department (ED) often face significant delays in diagnosis and treatment. These patients are frequently younger, underinsured, and experience multiple socioeconomic and systems-level barriers to accessing timely cancer care. Delays of more than 30 days have been associated with worse outcomes, including higher recurrence rates and reduced survival.\n\nThis pilot study will evaluate the feasibility and early impact of a community-based navigation program designed to improve access to timely care for ED-presenting HNC patients. The study embeds trained Community Health Support Specialists (CHSS) from the Engaging Navigators to Reduce Inequities in Cancer Health (ENRICH) program into the ED-to-treatment pathway. After ED discharge, CHSS staff will contact participants by telephone or text message to identify barriers to care-such as transportation, insurance, housing, or communication challenges-and connect them with appropriate community or institutional resources.\n\nAll participants will receive the CHSS navigation intervention. Outcomes will be compared with a historical cohort of similar ED-presenting HNC patients treated prior to program implementation. The primary outcomes are time from ED discharge to diagnostic biopsy and time from ED discharge to initiation of definitive treatment. Secondary outcomes include feasibility, measured as the proportion of participants who complete CHSS navigation, and exploratory analyses of the types of barriers identified and resolved.\n\nFindings from this pilot will generate preliminary data to inform larger studies aimed at improving access, reducing disparities, and accelerating treatment for head and neck cancer patients who first present in the emergency setting.",[187,188,189],"Head and Neck Neoplasms","Emergency Department Presentation","Head and Neck Cancer (H&N)",[191,192,193,194,195,196,197,198,199,200],"Emergency Department","Patient Navigation","Community Health Support","Health Equity","Cancer Care Access","Care Timeliness","Implementation Science","Engaging Navigators to Reduce Inequities in Cancer Health","ENRICH Program","Head and Neck Cancer","2026-01-20",{"date":203,"type":41},"2026-01-22",{"date":205,"type":22},"2026-02-01",{"date":207,"type":22},"2027-01-31",{"name":47,"class":48},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":16,"sex":17,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":76},"100610433","effects-of-upf-warning-labels-on-social-media-among-teens-and-young-adults-100610433","NCT07227519","Effects of UPF Warning Labels on Social Media Among Teens and Young Adults","Online Randomized Experiment Evaluating Ultra-Processed Food Warning Labels on Social Media Posts Among Teens and Young Adults","Inclusion Criteria:\n\n* Aged 13-29\n* Reside in the US\n* Can read and speak English\n\nExclusion Criteria:\n\n* Under the age of 13 or over 29\n* Reside outside of the United States\n* Unable to complete a survey in English","13 Years","29 Years",{"count":219,"type":22},1000,[25],"This study aims to evaluate whether Ultra-Processed Food (UPF) warning labels on social media posts improve consumer understanding and influence purchase intentions among teens and young adults. Participants aged 13-29 in the United States will be recruited and randomized into two groups: a control group (no label) and an intervention group (UPF warning). Participants will view social media posts featuring UPFs with or without warning labels and respond to survey questions following each post.",[223,224,225],"Nutrition","Healthy Diet","Food Preferences","2025-11-24",{"date":228,"type":41},"2025-12-02",{"date":230,"type":22},"2025-12-01",{"date":232,"type":22},"2025-12-20",{"name":47,"class":48},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":84,"minAge":242,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":252,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":173},"100573353","making-healthy-habits-stick-100573353","NCT06745180","Making Healthy Habits Stick","Making Healthy Habits Stick: Extended Contact Interventions to Promote Long-Term Physical Activity in Cancer Survivors","HABITS","Inclusion Criteria:\n\n* woman age of 19 or older\n* identifies as African American or Black\n* have a history of cancer\n* have completed post-primary treatment for cancer (i.e., chemotherapy, radiation)\n* agree to allow research team to confirm cancer diagnosis with your physician\n* If received surgery, must be at least 8 weeks post-surgery\n* willing to have regular physician provide medical clearance for study participation\n* willing to provide home address if qualified for the study\n* willing and able to use videoconference platform such as Zoom for study activities (must be both willing and able)\n* willing and able to send and\u002For receive text messages (must be both willing and able)\n* has US phone number\n* has an email address\n* if has no email address, must be willing to create one\n* English speaking\n* Able to ambulate without assistance (does not need to use a cane, a walker, or a wheelchair)\n* willing and able to complete 3-5 exercise session per week on their own for the duration of the study; if answered no, please explain\n* willing to attend individual and group sessions via videoconferences during study participation; if answered no, please explain.\n* willing to attend assessments via videoconference during study participation; if answered no, please explain.\n* willing to complete surveys during study participation; if answered no, please explain.\n\nExclusion Criteria:\n\n* Metastatic or recurrent cancer\n* another cancer diagnosis in the past 5 years (not including skin or cervical cancer in situ)\n* have severe orthopedic, joints or any other condition that stops individual from being active\n* unstable angina\n* have paint, tightness, or heaviness in chest EITHER when resting OR then physically active\n* have New York Heart Association class II, III, OR IV congestive heart failure\n* blood pressure has been over 160\u002F100 at least twice in the past 6 months (either number; 160 or 100)\n* have uncontrolled asthma\n* have interstitial lung disease that requires extra oxygen\n* have dementia or organize brain syndrome\n* have schizophrenia or active psychosis\n* have had a stroke or other problem that left individual disables or with paralysis (unable to move or feel any part of body)\n* have hearing problems that make it hard to carry on a phone conversation\n* blind or partially blind\n* planned surgery during the first 6 month of study participation (if unapproved by PI)\n* planned knee or hip surgery during the first 6 month of study participation\n* anticipate changes in usual medications during the first 6 months of study participation (if unapproved by PI)\n* have been told by a physician to only do exercise prescribed by a physician\n* have been told by a physician to limit physical activity\n* have a contraindication to engaging in moderate intensity aerobic exercise\n* have completed on average, more than 90 min\u002Fweek of moderate-intensity or more that 30 min\u002Fweek of vigorous exercise in the past 6 months\n* trouble with balance or moving around safely\n* are currently pregnant or anticipate pregnant during study participation\n* currently participating in another exercise study\n* have BMI ≥ 50","19 Years",{"count":244,"type":22},260,[25],"The aim of this project is to help increase physical activity maintenance in cancer survivors.",[248,249,250,251],"Cancer","Physical Activity","Cancer Survivor","Cancer Survivorship",[249,248,250,253,251],"Exercise","2025-09-26",{"date":256,"type":41},"2025-10-01",{"date":258,"type":41},"2025-01-27",{"date":260,"type":22},"2028-03-31",{"name":47,"class":48},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":17,"minAge":269,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":76},"100506737","supporting-infant-development-through-tummy-time-positioning-and-limiting-baby-gear-100506737","NCT05878275","Supporting Infant Development Through Tummy Time, Positioning, and Limiting Baby Gear","Supporting Infant Development: The Impact of a Tummy Time Intervention on Infant Development","Inclusion Criteria:\n\n1. Parent of the infant speaks and reads English\n2. Individual is the parent or legal guardian of the infant.\n3. Infant is 1 month of age or younger\n4. Infant was carried to at least 37-weeks' gestation\n5. Parent must own a cell phone will internet access and Zoom or Face Time capability\n6. Parent must have a working email address.\n7. Parent is over the age of 18 years\n8. Family resides within a 30-min driving distance from the University of Tennessee Health Science Center,\n9. Infant birthweight of at least 2500 g\u002F 5.5 pounds\n10. Parental report of no know medical condition, health complication or problem since birth\n11. that could have an impact on infant movement behaviors or development.\n12. Parent reports that infant does not have a diagnosis of Gastroesophageal reflux disease (GERD).\n13. Family does not expect to move from the area within 3 years of enrollment\n\nExclusion Criteria:\n\n1\\. Infant is regularly cared for by an adult other than their parent for 20 hours or more per week.","1 Day","4 Years",{"count":272,"type":22},50,[25],"The goal of this clinical trial is to examine the impact of an educational intervention on infant motor skill development. The main question it aims to answer is: Question 1) Does exposure to an educational intervention on infant development positively impact infant motor skill development? Researchers will compare the intervention group to the treatment as usual group see if there are differences in infant motor skill development.\n\nThe purpose of the proposed study is to determine if tummy time, play positions, screen time, and use of baby gear impacts early motor skill development in children. This is a Pilot study. A Pilot study is a small study that is carried out to collect information that will help in the planning of a larger study with the same topic.",[276,277],"Prone Position","Child Development",[276,279,280],"Tummy Time","Infant Development","2025-03-24",{"date":283,"type":41},"2025-03-28",{"date":285,"type":41},"2023-11-17",{"date":287,"type":22},"2028-12-31",{"name":47,"class":48},{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":84,"minAge":85,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":76},"100580858","phase-4-pain-with-differing-intraperitoneal-washes-at-the-end-of-laparoscopic-gynecologic-surgery-100580858","NCT06842771","Pain with Differing Intraperitoneal Washes At the End of Laparoscopic Gynecologic Surgery","Inclusion Criteria:\n\n* Age 18 years and older\n* Undergoing planned laparoscopic adnexal surgery as a day surgery procedure; The surgical site is the \"adnexa\" which contains the ovaries, fallopian tubes, and associated ligaments, vessels, and connective tissue. The \"adnexa\" does not include the uterus.\n* BMI 55.0 or less\n\nExclusion Criteria:\n\n* Under age 18\n* Undergoing a non-laparoscopic unplanned surgical procedure Patients having a laparoscopic partial or complete removal of the uterus, a hysterectomy, will NOT be included in this study population for enrollment.\n* septicemia\n* severe hemorrhage\n* severe hypotension or shock\n* arrhythmias\n* known hypersensitivity to bupivacaine or to any other local anesthetic agent\n* local infection at the injection site",{"count":296,"type":22},96,[90],"We hypothesize that instilling intraperitoneal Marcaine (without epinephrine) at the end of a non-total laparoscopic gynecologic surgery (adnexa only, which includes the ovaries, fallopian tubes, and associated ligaments, vessels, and connective tissue) will result in less pain and reduced opioid use postoperatively.",[300],"Laparoscopic Adnexal Surgery",[302,303,304,305],"laparoscopic gynecologic surgery","adnexal laparoscopic surgery","ovarian laparoscopic surgery","fallopian tube laparoscopic surgery","2025-02-18",{"date":308,"type":41},"2025-02-24",{"date":310,"type":22},"2025-03",{"date":312,"type":22},"2027-03",{"name":47,"class":48},{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":16,"sex":84,"minAge":85,"maxAge":117,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":76},"100572755","postoperative-bladder-filling-after-outpatient-laparoscopic-hysterectomy-and-time-to-discharge-100572755","NCT06737393","Postoperative Bladder Filling After Outpatient Laparoscopic Hysterectomy and Time to Discharge","Postoperative Bladder Filling After Outpatient Laparoscopic Hysterectomy and Time to Discharge: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 18 to 80\n* Undergoing planned laparoscopic hysterectomy as a day surgery procedure\n\nExclusion Criteria:\n\n* Women younger than 18 or older than 80 years of age\n* Undergoing a non-laparoscopic unplanned surgical procedure",{"count":322,"type":22},112,[25],"The investigators hypothesize that backfilling the bladder postoperatively will reduce time to spontaneous void and subsequent discharge from the post-anesthesia care unit.",[326,327],"Patient Discharge","Urinary Complication","2024-12-15",{"date":330,"type":41},"2024-12-17",{"date":332,"type":22},"2025-01-01",{"date":334,"type":22},"2026-01-01",{"name":47,"class":48},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":17,"minAge":342,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":358,"locationsCount":76},"100572297","does-starting-feeds-on-the-first-day-of-life-help-premature-infants-reach-full-volume-feeds-sooner-100572297","NCT06731439","Does Starting Feeds on the First Day of Life Help Premature Infants Reach Full Volume Feeds Sooner?","Inclusion Criteria:\n\n1. All infants less than or equal to 1000 g\n2. Clinical care team in agreement with patient's participation\n3. All mothers with pregnancies with EFW close to 1000g or less.\n\nExclusion Criteria:\n\n1 congenital malformations that may affect gastro intestinal perfusion\n\n2 Clinically progressing towards imminent death\n\n3 congenital gastrointestinal obstructions\n\n4 Mothers unlikely to deliver infants ≤ 1000g\n\n5 Infant on pressors other than dopamine given at \\\u003C 5mcg\u002Fkg\u002Fmin. Dopamine is an exclusion if administered at a dose exceeding 5mcg\u002Fkg\u002Fmin.\n\n6 Mothers who are not in a sound mental state to be consented either to their critical condition, intubated, sedated, for examples\n\n7 Mothers who are critically ill where by it is felt that mom will not be able to participate in the consent","1 Minute","6 Hours",{"count":345,"type":22},248,[25],"Feeding advancements in ELBW infants have evolved over decades. The fear of causing mortality and morbidity, notably NEC, have made providers cautious when advancing feeds. ELBW infants initially remained NPO for several days before initiating trophic feeds. However, data then showed that there was no increase in mortality and morbidity if trophic feeds were initiated earlier. Then data showed that a short duration of trophic feeds did not increase mortality and morbidity when compared to a prolonged duration. More recent data showed that enteral feeding should be initiated early, preferably within 24 hours of birth, because it may promote feeding tolerance, shorten the time to reach total enteral feeding, and reduce the incidence of extrauterine growth restriction and late onset sepsis without increasing the risk of developing NEC. The management of enteral nutrition in ELBW infants is still very variable. For example, there is no consensus on the optimal time point after birth at which enteral nutrition can be started. This study evaluates the benefits of starting feeds by 6 hours of life Purpose: The primary aim of this study is to evaluate if in infants ≤ 1000g birth weight, is there a benefit initiating feeds by 6 hours of life (compared to current feeding practice data of 3 days of life) on decreasing the time to attain full feeds in the first 30 days of life. The secondary aim is to evaluate if antenatal feeding discussions would streamline feeding management post-delivery.",[349,350,351],"Extra Uterine Growth Restriction","Premature Infant Disease","VLBW - Very Low Birth Weight Infant","2024-12-09",{"date":354,"type":41},"2024-12-12",{"date":356,"type":41},"2024-06-01",{"date":45,"type":22},{"name":47,"class":48},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":376,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":76},"100555013","phase-4-low-dose-ketamine-infusion-during-burn-wound-care-100555013","NCT06506565","Low-Dose Ketamine Infusion During Burn Wound Care","A Randomized, Placebo-Controlled, Double-Blind Evaluation of Low-Dose Ketamine Infusion During Burn Wound Care Procedures to Improve Pain Intensity and Reduce Opioid Consumption","IMPROVE","Inclusion Criteria:\n\n* Admitted to burn service with thermal injury\n\nExclusion Criteria:\n\n* unable\u002Funwilling to consent within 72 hours\n* unable to report NRS\n* known contraindication to ketamine\n* \\\u003C than 18 years of age\n* pregnant\n* incarcerated\n* TBSA over 50 %",{"count":368,"type":22},140,[90],"The current standard of care (SOC) (i.e. fentanyl and midazolam) offers limited efficacy for preventing or relieving pain. Ketamine infusions may provide the benefits of analgesia, minimize adverse events, and reduce opioid use. The purpose of this study is to determine if adding a low dose ketamine infusion during wound care will safely provide pain relief for patients with burn injury.",[372,373,374,375],"Burn","Pain","Dissociation","Opioid",[377,378,379,380],"ketamine","burn","opioid","analgesia",{"date":382,"type":41},"2024-12-13",{"date":384,"type":41},"2024-07-08",{"date":386,"type":22},"2025-12",{"name":47,"class":48},{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":342,"maxAge":86,"enrollmentInfo":396,"targetDuration":398,"studyType":399,"phases":4,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":411},"100247890","pregnancies-complicated-by-fetal-anomalies-100247890","NCT02505464","Pregnancies Complicated by Fetal Anomalies","Characteristics of Pregnancies Complicated by Fetal Anomalies","FAR","Inclusion Criteria:\n\n* Pregnant females\n\n  * age 8 years to 50 years\n  * who have referred to the clinic for high risks pregnancies\n* Infants (male and female) born with anomalies\n\nExclusion Criteria:\n\n* Non-pregnant females.",{"count":397,"type":22},500,"12 Months","OBSERVATIONAL","The focus of this research is to create a repository of ultrasonographic images and their corresponding medical data from pregnant women (the mothers of the fetuses that are imaged), focusing on fetal anomalies. These women will visit the obstetrical clinics at Regional One Health and the Le Bonheur Fetal Center.",[402,403],"Pregnancy","Congenital Abnormalities","2024-12-04",{"date":352,"type":41},{"date":407,"type":41},"2015-05",{"date":409,"type":22},"2028-04",{"name":47,"class":48},5,{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":16,"sex":84,"minAge":85,"maxAge":117,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":76},"100557022","opioid-prescribing-practices-in-laparoscopic-gynecologic-surgery-100557022","NCT06532708","Opioid Prescribing Practices in Laparoscopic Gynecologic Surgery","Prospective Study of Opioid Prescribing Practices in Laparoscopic Gynecologic Surgery","Inclusion Criteria:\n\n* Women aged 18 to 80\n* Undergoing planned laparoscopic hysterectomy as a day surgery procedure\n\nExclusion Criteria:\n\n* Women aged 18 to 80\n* Undergoing a non-laparoscopic unplanned surgical procedure\n* Patients with a history of opioid use disorder or current opioid use disorder",{"count":119,"type":22},[25],"The purpose of this study is to compare opioid prescribing practices by either routine provider prescribing practices, or with the use of a calculator, i.e., the Opioid Calculator, published by the University of Michigan (www.opioidcalculator.org), with the intent of decreasing the number of pills.",[423,424],"Opioid Use","Postoperative Pain","2024-07-31",{"date":427,"type":41},"2024-08-02",{"date":429,"type":41},"2024-07-12",{"date":431,"type":22},"2024-10-31",{"name":47,"class":48},{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":16,"sex":84,"minAge":85,"maxAge":117,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":76},"100555186","pain-with-differing-insufflation-pressures-during-laparoscopic-hysterectomy-100555186","NCT06508814","Pain With Differing Insufflation Pressures During Laparoscopic Hysterectomy","Inclusion Criteria:\n\n* Women aged 18 to 80\n* BMI 55.0 or less\n* Laparoscopic hysterectomy surgery planned\n\nExclusion Criteria:\n\n* Women younger than 18 or older than 80 years of age\n* BMI over 55.0\n* Laparoscopic hysterectomy surgery not planned",{"count":440,"type":22},100,[25],"The purpose of this study is to determine the effect of decreased insufflation pressure on postoperative pain, analgesic use, and surgical safety and feasibility for laparoscopic hysterectomy.",[444],"Post Operative Pain","2024-07-19",{"date":447,"type":41},"2024-07-23",{"date":449,"type":41},"2024-06-10",{"date":451,"type":22},"2025-06-10",{"name":47,"class":48},{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":16,"sex":17,"minAge":459,"maxAge":460,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":462,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":472,"leadSponsor":474,"locationsCount":4},"100549412","phase-3-enteral-zinc-supplementation-in-very-low-birth-weight-infants-100549412","NCT06433674","Enteral Zinc Supplementation in Very Low Birth Weight Infants","Inclusion Criteria:\n\n1. Birth weight \\\u003C 1500 grams\n2. Infant is tolerating at least 100 ml\u002Fkg\u002Fday of enteral feeds\n3. At least 25wks PMA.\n\nExclusion Criteria:\n\n* Major congenital malformations especially anomaly of the GI tract\n* Major congenital heart disease (i.e.: ductal dependent lesion)\n* Previously diagnosed necrotizing enterocolitis (stage 2 or 3), bowel perforation, or bowel resection\n* Infant who has tolerated ≥100 ml\u002Fkg\u002Fday prior to admission.","25 Weeks","36 Weeks",{"count":272,"type":22},[463],"PHASE3","The goal of this clinical trial is to observe for changes in rate of weight gain in the very low birth weight (VLBW) infants by adding an enteral Zinc supplement of 1 mg\u002Fkg\u002Fday of elemental zinc. The main question it aims to answer:\n\n• Does an enteral Zinc supplement of 1 mg\u002Fkg\u002Fday increase rate of weight gain in VLBW infants Researches will compare the experimental group to a placebo group to see if there is a statistical difference in rate of weight gain between the two groups\n\n* Once the participants have reached 100 ml\u002Fkg\u002Fday of enteral feeds. The participants will be randomized to one of two groups. The treatment group will receive \\~1 mg\u002Fkg\u002Fday of elemental enteral Zinc, and the control group to receive similar amount of enteral sterile water put in a colored syringe. The Zinc Supplement would be Zinc Sulfate. The primary team would otherwise be managing the patient's feeding using our hospital's feeding protocol. As long as the patient is tolerating 100 ml\u002Fkg\u002Fday of enteral feeds, the Zinc Supplement will continue until 36 weeks postmenstrual age (PMA) or hospital discharge, whichever comes first.\n* The participants will have three Zinc levels measured: once prior to Zinc Supplementation, once at around the four week mark, and once at the completion of therapy.",[466,467],"Very Low Birth Weight Infant","Nutritional Deficiency","2024-06-04",{"date":470,"type":41},"2024-06-06",{"date":356,"type":22},{"date":473,"type":22},"2025-07-01",{"name":47,"class":48},{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":483,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":76},"100338458","y90-radioembolization-dose-delivery-and-radiation-exposure-assessment-100338458","NCT03686709","Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment","Inclusion Criteria:\n\n* All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study\n* Must be able to schedule and tolerate additional PET\u002FCT imaging following therapy\n* Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.\n\nExclusion Criteria:\n\n* Patients that are not candidates for Y90 radioembolization therapy\n* Patients that cannot tolerate additional imaging procedures following therapy\n* Patients that cannot tolerate the additional blood draws required for this study\n* Patients whose schedule does not allow them to remain at the hospital for the additional PET\u002FCT imaging study",{"count":482,"type":22},20,[25],"The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.",[486,487],"Hepatocellular Carcinoma","Radiation Exposure","2018-09-25",{"date":490,"type":41},"2018-09-27",{"date":492,"type":41},"2018-06-19",{"date":494,"type":22},"2019-12-31",{"name":47,"class":48},""]